2023 ESC guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the …

RA Byrne, X Rossello, JJ Coughlan… - … Heart Journal: Acute …, 2024 - academic.oup.com
2023 ESC Guidelines for the management of acute coronary syndromes Page 1 2023 ESC
Guidelines for the management of acute coronary syndromes Developed by the task force on …

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice …

FLJ Visseren, F Mach, YM Smulders… - European heart …, 2021 - academic.oup.com
Atherosclerotic cardiovascular (CV) disease (ASCVD) incidence and mortality rates are
declining in many countries in Europe, but it is still a major cause of morbidity and mortality …

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and …

Authors/Task Force Members:… - European journal of …, 2022 - Wiley Online Library
Abstract Document Reviewers: Rudolf A. de Boer (CPG Review Coordinator)(Netherlands),
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and …

TA McDonagh, M Metra, M Adamo… - European heart …, 2021 - academic.oup.com
The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …

Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis

N Sattar, DK McGuire, I Pavo, GJ Weerakkody… - Nature medicine, 2022 - nature.com
Tirzepatide is a novel, once weekly, dual GIP/GLP-1 receptor agonist and is under
development for the treatment of type 2 diabetes (T2D) and obesity. Its association with …

[HTML][HTML] Cardiovascular events with finerenone in kidney disease and type 2 diabetes

B Pitt, G Filippatos, R Agarwal, SD Anker… - … England Journal of …, 2021 - Mass Medical Soc
Background Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, has
favorable effects on cardiorenal outcomes in patients with predominantly stage 3 or 4 …

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised …

N Sattar, MMY Lee, SL Kristensen… - The lancet Diabetes & …, 2021 - thelancet.com
Background GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE)
in patients with type 2 diabetes. However, uncertainty regarding kidney outcomes persists …

Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation

I Lingvay, P Sumithran, RV Cohen, CW le Roux - The Lancet, 2022 - thelancet.com
Obesity is now recognised as a disease that is associated with serious morbidity and
increased mortality. One of its main metabolic complications is type 2 diabetes, as the two …

Chronic kidney disease

K Kalantar-Zadeh, TH Jafar, D Nitsch, BL Neuen… - The lancet, 2021 - thelancet.com
Chronic kidney disease is a progressive disease with no cure and high morbidity and
mortality that occurs commonly in the general adult population, especially in people with …

2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association …

Writing Committee Members, SS Virani… - Journal of the American …, 2023 - jacc.org
Abstract Aim The “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management
of Patients With Chronic Coronary Disease” provides an update to and consolidates new …